Noble Capital Markets initiated coverage on Cadrenal Therapeutics with a new price target

12/18/23 8:12:12 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Noble Capital Markets initiated coverage of Cadrenal Therapeutics with a rating of Outperform and set a new price target of $4.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CVKD

Date	Price Target	Rating	Analyst
12/18/2023	$4.00	Outperform	Noble Capital Markets